ABIVAX Shares Climb 3.51% at Close on November 10

Strong Daily and Annual Performance

Closing at 91.50 euros, ABIVAX recorded a 3.51% increase from the previous day's 88.4 euros. This rise was more significant than that of the CAC 40, which gained 1.32% on the day, confirming the biotech stock's outperformance in a generally favorable market context. However, the trading volume remained moderate, with only 0.27% of the capital traded, indicating limited liquidity for this small-cap stock which has long been overlooked by retail investors. Over longer investment horizons, ABIVAX's performance remains spectacular. Over one year, the stock has surged by 852.10%, significantly outperforming the CAC 40's 9.77% over the same period. Over the past three months, the stock has climbed 51.49%, while the past week saw a modest rebound of 0.66%. These performances highlight the growing attractiveness of ABIVAX to investors interested in the therapeutic potential of its clinical pipeline. This trajectory underscores the high volatility typical of biotech stocks, often linked to clinical advancements or setbacks that shape the risk-reward profile. The Paris-based biotech, listed on Euronext Paris and Nasdaq, is increasingly recognized by both American and European markets.

Positive Clinical Trial Developments

This recent progress is due to positive developments announced this week in clinical trials. On November 3, ABIVAX reported results from the phase 3 ABTECT induction trials evaluating obezimod for the treatment of moderate to severe ulcerative colitis. Patient-reported data from the eight-week trials showed significant improvements in quality of life metrics. According to these results, 37% of patients receiving the daily 50 milligram dose reported no intestinal urgency at week eight, compared to 18.1% in the placebo group. Regarding nocturnal bowel movements, 47.6% of patients on this dose reported no symptoms, compared to 24.7% in the placebo group. The trials also measured improvements related to fatigue, with 17.1% of patients in the 50 milligram group reporting remission at week eight, compared to 7.7% in the placebo group. These phase 3 data are generally critical milestones in the development of new treatments. These results prompted several target price upgrades by the analytical community. On November 6, Wolfe Research initiated coverage of the stock with an outperform rating and a target of 176 US dollars, marking a confident entry by the broker into the monitoring of the stock. Leerink Partners also raised its target to 115 dollars, while Citizens reiterated its outperform recommendation with a target of 114 dollars, highlighting the positive safety data and therapeutic potential of the obezimod candidate for the treatment of ulcerative colitis and Crohn's disease. These multiple analyst adjustments reinforce market confidence in ABIVAX's commercial prospects.

Technical Outlook

Technically, ABIVAX is now well above its main moving averages, with a price of 91.50 euros positioned above the 50-day moving average at 76.59 euros and well detached from the 200-day moving average set at 31.55 euros. The Relative Strength Index (RSI) stands at 63, placing the stock in a neutral zone without any extreme overbought signals. The short-term resistance threshold is around 90.90 euros, already surpassed at this Monday's close. On the upper Bollinger band, set at 91.30 euros, the stock is trading in close proximity. The MACD indicator displays a line at 3.44 and a signal line at 3.19, showing a slight positive divergence of 0.25. The lower support threshold remains positioned at 70.00 euros.